The medication finest recognized for dramatic weight reduction are quietly turning into a flashpoint within the competitors for expertise, and employers who’ve been sluggish to behave on protection could also be working out of time.
In keeping with NFP’s (an Aon firm) 2026 U.S. Advantages Development Report, almost one-third of staff say they might change employers to achieve entry to GLP-1 protection, elevating these medicines from a line merchandise within the pharmacy finances to a workforce technique drawback.
On the identical time, 51% of employers now cite GLP-1 diabetes and weight-loss medicines as the highest driver of prescription drug spend, surpassing oncology and autoimmune remedies.
The result’s a strategic bind. Employers can’t simply afford to cowl these medication broadly, and so they more and more can’t afford to not.
Two tiers of GLP-1 protection
The NFP report describes a market that has successfully break up in two: GLP-1 protection for diabetes, the place scientific justification is clearer, and protection for weight administration, the place employer choices fluctuate dramatically and cost-benefit calculations stay unsettled.
Some employers have been reluctant to increase protection to the weight-loss indication. Protection for weight problems medication, together with GLP‑1 medicines, rose to 44% of huge employers (500+ staff) in 2024, and 64% of the most important employers (20,000+ staff) now provide this protection, in line with knowledge from Mercer.
Pharmacy profit managers make it comparatively straightforward to toggle that protection distinction on or off, and a great quantity have achieved so. However worker expectations, formed by the cultural ubiquity of medication like Ozempic and Wegovy, haven’t adopted swimsuit.
Worker satisfaction with prescription cost-sharing displays the stress. The NFP report discovered satisfaction dropped from 73% to 66% 12 months over 12 months, and 47% of staff now use web sites or apps to search out decrease drug costs. HR leaders can take this as a sign that out-of-pocket prices have gotten unattractive for a lot of staff.
Learn extra | Exploding GLP-1 prices: How employers are scrambling to handle
New GLP-1 fashions emerge, however tradeoffs stay
The market is starting to reply. CVS Caremark not too long ago introduced a collaboration with telehealth firm eMed that permits eligible staff to buy GLP-1s on-line with wraparound scientific help, together with weekly check-ins, facet impact administration and biannual blood testing. Employers can decide how a lot of the associated fee to subsidize, providing a center path between full formulary protection and nothing in any respect.
Aon, which piloted the same eMed program for its personal staff, reported that contributors stayed on the treatment longer and noticed significant enhancements in weight and BMI. About 9% of eligible Aon staff enrolled, in line with reporting in Axios.
Nonetheless, the economics are unresolved. Analysis from the Worker Profit Analysis Institute estimates that including GLP-1 protection for weight reduction may enhance employer medical health insurance premiums by between 5.3% and 13.8%, relying on eligibility standards and adherence patterns. Any downstream financial savings from improved well being outcomes, in the meantime, might take years to materialize.
Regardless of the prospect of ready for long-term, health-driven premium financial savings, the NFP knowledge means that doing nothing carries its personal value. With almost a 3rd of staff prepared to alter jobs over this profit, GLP-1 protection is now not a scientific resolution delegated to the advantages group. It’s a complete rewards resolution that belongs in conversations about expertise competitiveness.
Hybrid fashions just like the eMed partnership might provide employers a option to act with out absolutely absorbing the associated fee, however the window for a measured response is narrowing as worker expectations proceed to rise.
